{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:59:14Z","timestamp":1793336354378,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:00:00Z","timestamp":1718236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:00:00Z","timestamp":1718236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>Our aim was twofold. First, to validate Anali scores with and without gadolinium (ANALI<jats:sub>Gd<\/jats:sub> and ANALI<jats:sub>NoGd<\/jats:sub>) in primary sclerosing cholangitis (PSC) patients. Second, to compare the ANALIs prognostic ability with the recently-proposed potential functional stricture (PFS).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>This retrospective study included 123 patients with a mean age of 41.5 years, who underwent gadoxetic acid-enahnced MRI (GA-MRI). Five readers independently evaluated all images for calculation of ANALI<jats:sub>Gd<\/jats:sub> and ANALI<jats:sub>NoGd<\/jats:sub> scores based upon following criteria: intrahepatic bile duct change severity, hepatic dysmorphia, liver parenchymal heterogeneity, and portal hypertension. In addition, hepatobiliary contrast excretion into first-order bile ducts was evaluated on 20-minute hepatobiliary-phase (HBP) images to assess PFS. Inter- and intrareader agreement were calculated (Fleiss\u00b4and Cohen kappas). Kaplan-Meier curves were generated for survival analysis. ANALI<jats:sub>NoGd<\/jats:sub>, ANALI<jats:sub>Gd<\/jats:sub>, and PFS were correlated with clinical scores, labs and outcomes (Cox regression analysis).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Inter-reader agreement was almost perfect\u00a0(\u03f0\u2009=\u20090.81) for PFS, but only moderate-(\u03f0\u2009=\u20090.55) for binary ANALI<jats:sub>NoGd<\/jats:sub>. For binary ANALI<jats:sub>Gd<\/jats:sub>, the agreement was slightly better on HBP (\u03f0\u2009=\u20090.64) than on arterial-phase (AP) (\u03f0\u2009=\u20090.53). Univariate Cox regression showed that outcomes for decompensated cirrhosis, orthotopic liver transplantation or death significantly correlated with PFS (HR (hazard ratio)\u2009=\u20093.15, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), ANALI<jats:sub>NoGd<\/jats:sub> (HR\u2009=\u20096.42, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), ANALI<jats:sub>Gd<\/jats:sub>HBP (HR\u2009=\u20093.66, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and ANALI<jats:sub>Gd<\/jats:sub>AP (HR\u2009=\u20093.79, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Multivariate analysis identified the PFS, all three ANALI scores, and Revised Mayo Risk Score as independent risk factors for outcomes (HR 3.12, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001; 6.12, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001; 3.56, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001;3.59, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001; and 4.13, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001, respectively).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>ANALI<jats:sub>NoGd<\/jats:sub> and GA-MRI-derived ANALI scores and PFS could noninvasively predict outcomes in PSC patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Clinical relevance statement<\/jats:title>\n                <jats:p>The combined use of Anali scores and the potential functional stricture (PFS), both derived from unenhanced-, and gadoxetic acid enhanced-MRI, could be applied as a diagnostic and prognostic imaging surrogate for counselling and monitoring primary sclerosing cholangitis patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Key Points<\/jats:title>\n                <jats:p><jats:list list-type=\"bullet\">\n                  <jats:list-item>\n                    <jats:p><jats:italic>Primary sclerosing cholangitis patients require radiological monitoring to assess disease stability and for the presence and type of complications<\/jats:italic>.<\/jats:p>\n                  <\/jats:list-item>\n                  <jats:list-item>\n                    <jats:p><jats:italic>A contrast-enhanced MRI algorithm based on potential functional stricture and ANALI scores risk-stratified these patients<\/jats:italic>.<\/jats:p>\n                  <\/jats:list-item>\n                  <jats:list-item>\n                    <jats:p><jats:italic>Unenhanced ANALI score had a high negative predictive value, indicating some primary sclerosing cholangitis patients can undergo non-contrast MRI surveillance<\/jats:italic>.<\/jats:p>\n                  <\/jats:list-item>\n                <\/jats:list><\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1007\/s00330-024-10787-4","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T15:03:15Z","timestamp":1718290995000},"page":"7632-7644","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Disease severity prognostication in primary sclerosing cholangitis: a validation of the Anali scores and comparison with the potential functional stricture"],"prefix":"10.1007","volume":"34","author":[{"given":"Sarah","family":"Poetter-Lang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3527-404X","authenticated-orcid":false,"given":"Ahmed","family":"Ba-Ssalamah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Messner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Bastati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Ambros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Kristic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Kittinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svitlana","family":"Pochepnia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami A.","family":"Ba-Ssalamah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline. C.","family":"Hodge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emina","family":"Halilbasic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhakar K.","family":"Venkatesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Kartalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Ringe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Arriv\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Trauner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,13]]},"reference":[{"key":"10787_CR1","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1002\/hep.24247","volume":"53","author":"NA Molodecky","year":"2011","unstructured":"Molodecky NA, Kareemi H, Parab R et al (2011) Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis. Hepatology 53:1590\u20131599","journal-title":"Hepatology"},{"key":"10787_CR2","doi-asserted-by":"publisher","first-page":"152","DOI":"10.4103\/sjg.SJG_478_18","volume":"25","author":"D Segal","year":"2019","unstructured":"Segal D, Marotta P, Mosli M, Zou G, Feagan BG, Al-Judaibi B (2019) The role of imaging in determining prognosis for primary sclerosing cholangitis: a systematic review. Saudi J Gastroenterol 25:152\u2013158","journal-title":"Saudi J Gastroenterol"},{"key":"10787_CR3","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1155\/2008\/824168","volume":"22","author":"MG Silveira","year":"2008","unstructured":"Silveira MG, Lindor KD (2008) Primary sclerosing cholangitis. Can J Gastroenterol 22:689\u2013698","journal-title":"Can J Gastroenterol"},{"key":"10787_CR4","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/S0025-6196(11)64614-4","volume":"75","author":"WR Kim","year":"2000","unstructured":"Kim WR, Therneau TM, Wiesner RH et al (2000) A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc 75:688\u2013694","journal-title":"Mayo Clin Proc"},{"key":"10787_CR5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1148\/radiol.10091953","volume":"256","author":"M Dave","year":"2010","unstructured":"Dave M, Elmunzer BJ, Dwamena BA, Higgins PD (2010) Primary sclerosing cholangitis: meta-analysis of diagnostic performance of MR cholangiopancreatography. Radiology 256:387\u2013396","journal-title":"Radiology"},{"key":"10787_CR6","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/hep.26620","volume":"59","author":"A Ruiz","year":"2014","unstructured":"Ruiz A, Lemoinne S, Carrat F, Corpechot C, Chazouill\u00e8res O, Arriv\u00e9 L (2014) Radiologic course of primary sclerosing cholangitis: assessment by three-dimensional magnetic resonance cholangiography and predictive features of progression. Hepatology 59:242\u2013250","journal-title":"Hepatology"},{"key":"10787_CR7","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1016\/j.cgh.2019.03.013","volume":"17","author":"S Lemoinne","year":"2019","unstructured":"Lemoinne S, Cazzagon N, El Mouhadi S et al (2019) Simple magnetic resonance scores associate with outcomes of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 17:2785\u20132792.e3","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10787_CR8","doi-asserted-by":"crossref","unstructured":"Grave EC, Loehfelm T, Corwin MT et al (2024) Interobserver agreement and prognostic value of image-based scoring systems in patients with primary sclerosing cholangitis. Abdom Radiol (NY) 49:60\u201368","DOI":"10.1007\/s00261-023-04051-4"},{"key":"10787_CR9","doi-asserted-by":"publisher","first-page":"109884","DOI":"10.1016\/j.ejrad.2021.109884","volume":"142","author":"A Grigoriadis","year":"2021","unstructured":"Grigoriadis A, Ringe KI, Andersson M, Kartalis N, Bergquist A (2021) Assessment of prognostic value and interreader agreement of ANALI scores in patients with primary sclerosing cholangitis. Eur J Radiol 142:109884","journal-title":"Eur J Radiol"},{"key":"10787_CR10","doi-asserted-by":"crossref","unstructured":"Poetter-Lang S, Messner A, Bastati N et al (2023) Diagnosis of functional strictures in patients with primary sclerosing cholangitis using hepatobiliary contrast-enhanced MRI: a proof-of-concept study. Eur Radiol 33:9022\u20139037","DOI":"10.1007\/s00330-023-09915-3"},{"key":"10787_CR11","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1055\/s-0043-107029","volume":"49","author":"L Aabakken","year":"2017","unstructured":"Aabakken L, Karlsen TH, Albert J et al (2017) Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the study of the liver (EASL) clinical guideline. Endoscopy 49:588\u2013608","journal-title":"Endoscopy"},{"key":"10787_CR12","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1053\/he.2000.5852","volume":"31","author":"M Malinchoc","year":"2000","unstructured":"Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC (2000) A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 31:864\u2013871","journal-title":"Hepatology"},{"key":"10787_CR13","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling RK, Lissen E, Clumeck N et al (2006) Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology 43:1317\u20131325","journal-title":"Hepatology"},{"key":"10787_CR14","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/S1665-2681(19)31836-8","volume":"7","author":"A Loaeza-del-Castillo","year":"2008","unstructured":"Loaeza-del-Castillo A, Paz-Pineda F, Oviedo-C\u00e1rdenas E, S\u00e1nchez-Avila F, Vargas-Vor\u00e1ckov\u00e1 F (2008) AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis. Ann Hepatol 7:350\u2013357","journal-title":"Ann Hepatol"},{"key":"10787_CR15","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","volume":"33","author":"PJ Johnson","year":"2015","unstructured":"Johnson PJ, Berhane S, Kagebayashi C et al (2015) Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 33:550\u2013558","journal-title":"J Clin Oncol"},{"key":"10787_CR16","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1002\/hep.30479","volume":"69","author":"EC Goode","year":"2019","unstructured":"Goode EC, Clark AB, Mells GF et al (2019) Factors associated with outcomes of patients with primary sclerosing cholangitis and development and validation of a risk scoring system. Hepatology 69:2120\u20132135","journal-title":"Hepatology"},{"key":"10787_CR17","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1002\/hep.26565","volume":"58","author":"K Boonstra","year":"2013","unstructured":"Boonstra K, Weersma RK, van Erpecum KJ et al (2013) Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology 58:2045\u20132055","journal-title":"Hepatology"},{"key":"10787_CR18","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.jhep.2019.06.012","volume":"71","author":"JC Goet","year":"2019","unstructured":"Goet JC, Floreani A, Verhelst X et al (2019) Validation, clinical utility and limitations of the Amsterdam-Oxford model for primary sclerosing cholangitis. J Hepatol 71:992\u2013999","journal-title":"J Hepatol"},{"key":"10787_CR19","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.5152\/tjg.2019.301019","volume":"30","author":"S Acar","year":"2019","unstructured":"Acar S, Akyildiz M (2019) A new prognostic model for primary sclerosing cholangitis. Turk J Gastroenterol 30:1004\u20131006","journal-title":"Turk J Gastroenterol"},{"key":"10787_CR20","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.ejrad.2018.10.006","volume":"108","author":"P Khoshpouri","year":"2018","unstructured":"Khoshpouri P, Ameli S, Ghasabeh MA et al (2018) Correlation between quantitative liver and spleen volumes and disease severity in primary sclerosing cholangitis as determined by Mayo risk score. Eur J Radiol 108:254\u2013260","journal-title":"Eur J Radiol"},{"key":"10787_CR21","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.cgh.2018.05.011","volume":"17","author":"J Schulze","year":"2019","unstructured":"Schulze J, Lenzen H, Hinrichs JB et al (2019) An imaging biomarker for assessing hepatic function in patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 17:192\u2013199.e3","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10787_CR22","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/hep.29113","volume":"66","author":"A Unalp-Arida","year":"2017","unstructured":"Unalp-Arida A, Ruhl CE (2017) Liver fibrosis scores predict liver disease mortality in the United States population. Hepatology 66:84\u201395","journal-title":"Hepatology"},{"key":"10787_CR23","doi-asserted-by":"publisher","first-page":"6600","DOI":"10.1007\/s00330-019-06182-z","volume":"29","author":"L Beer","year":"2019","unstructured":"Beer L, Mandorfer M, Bastati N et al (2019) Inter- and intra-reader agreement for gadoxetic acid-enhanced MRI parameter readings in patients with chronic liver diseases. Eur Radiol 29:6600\u20136610","journal-title":"Eur Radiol"},{"key":"10787_CR24","doi-asserted-by":"crossref","unstructured":"Fujita K, Nomura T, Morishita A et al (2019) Prediction of transplant-free survival through Albumin-Bilirubin score in primary biliary cholangitis. J Clin Med 8;1258.","DOI":"10.3390\/jcm8081258"},{"key":"10787_CR25","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1136\/gutjnl-2016-313681","volume":"67","author":"EM de Vries","year":"2018","unstructured":"de Vries EM, Wang J, Williamson KD et al (2018) A novel prognostic model for transplant-free survival in primary sclerosing cholangitis. Gut 67:1864\u20131869","journal-title":"Gut"},{"key":"10787_CR26","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1148\/rg.266055730","volume":"26","author":"C Hoeffel","year":"2006","unstructured":"Hoeffel C, Azizi L, Lewin M et al (2006) Normal and pathologic features of the postoperative biliary tract at 3D MR cholangiopancreatography and MR imaging. Radiographics 26:1603\u20131620","journal-title":"Radiographics"},{"key":"10787_CR27","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1002\/hep.29293","volume":"66","author":"C Schramm","year":"2017","unstructured":"Schramm C, Eaton J, Ringe KI, Venkatesh S, Yamamura J, MRI working group of the IPSCSG (2017) Recommendations on the use of magnetic resonance imaging in PSC-A position statement from the International PSC Study Group. Hepatology 66:1675\u20131688","journal-title":"Hepatology"},{"key":"10787_CR28","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/s003300050145","volume":"7","author":"P Prassopoulos","year":"1997","unstructured":"Prassopoulos P, Daskalogiannaki M, Raissaki M, Hatjidakis A, Gourtsoyiannis N (1997) Determination of normal splenic volume on computed tomography in relation to age, gender and body habitus. Eur Radiol 7:246\u2013248","journal-title":"Eur Radiol"},{"key":"10787_CR29","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1016\/j.cgh.2018.12.033","volume":"17","author":"F Jung","year":"2019","unstructured":"Jung F, Cazzagon N, Vettorazzi E et al (2019) Rate of spleen length progression is a marker of outcome in patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 17:2613\u20132615","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10787_CR30","unstructured":"Hartling L, Hamm M, Milne A et al (2012) In Validity and Inter-Rater Reliability Testing of Quality Assessment Instruments. Rockville (MD)"},{"key":"10787_CR31","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/ajg.2015.112","volume":"110","author":"KD Lindor","year":"2015","unstructured":"Lindor KD, Kowdley KV, Harrison EM (2015) ACG clinical guideline: primary sclerosing cholangitis. Am J Gastroenterol 110:646\u2013659. quiz 660","journal-title":"Am J Gastroenterol"},{"key":"10787_CR32","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1136\/gut.51.4.562","volume":"51","author":"CY Ponsioen","year":"2002","unstructured":"Ponsioen CY, Vrouenraets SM, Prawirodirdjo W et al (2002) Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population. Gut 51:562\u2013566","journal-title":"Gut"},{"key":"10787_CR33","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jhep.2009.01.023","volume":"51","author":"G Rudolph","year":"2009","unstructured":"Rudolph G, Gotthardt D, Kl\u00f6ters-Plachky P, Kulaksiz H, Rost D, Stiehl A (2009) Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis. J Hepatol 51:149\u2013155","journal-title":"J Hepatol"},{"key":"10787_CR34","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1016\/S0140-6736(13)60096-3","volume":"382","author":"GM Hirschfield","year":"2013","unstructured":"Hirschfield GM, Karlsen TH, Lindor KD, Adams DH (2013) Primary sclerosing cholangitis. Lancet 382:1587\u20131599","journal-title":"Lancet"},{"key":"10787_CR35","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1136\/gutjnl-2018-316801","volume":"68","author":"C Rupp","year":"2019","unstructured":"Rupp C, Hippchen T, Bruckner T et al (2019) Effect of scheduled endoscopic dilatation of dominant strictures on outcome in patients with primary sclerosing cholangitis. Gut 68:2170\u20132178","journal-title":"Gut"},{"key":"10787_CR36","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1056\/NEJM200102083440604","volume":"344","author":"P Hammel","year":"2001","unstructured":"Hammel P, Couvelard A, O'Toole D et al (2001) Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N Engl J Med 344:418\u2013423","journal-title":"N Engl J Med"},{"key":"10787_CR37","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1002\/hep4.1194","volume":"2","author":"MB Hilscher","year":"2018","unstructured":"Hilscher MB, Tabibian JH, Carey EJ, Gostout CJ, Lindor KD (2018) Dominant strictures in primary sclerosing cholangitis: a multicenter survey of clinical definitions and practices. Hepatol Commun 2:836\u2013844","journal-title":"Hepatol Commun"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-024-10787-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-024-10787-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-024-10787-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T23:03:06Z","timestamp":1731452586000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-024-10787-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,13]]},"references-count":37,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["10787"],"URL":"https:\/\/doi.org\/10.1007\/s00330-024-10787-4","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,13]]},"assertion":[{"value":"11 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The scientific guarantor of this publication is Dr. Ahmed Ba-Ssalamah.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"<b>Michael Trauner<\/b> received grant support from Albireo, Cymabay, Falk, Gilead, Intercept, MSD, and Takeda, honoraria for consulting from BiomX, Boehringer Ingelheim, Falk, Genfit, Gilead, Intercept, Janssen, MSD, Novartis, Phenex, and Regulus, speaker fees from BMS, Falk, Gilead, Intercept and MSD, as well as travel support from Abbvie, Falk, Gilead, and Intercept. The other authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article. <b>Nikolaos Kartalis<\/b> is a member of the <i>European Radiology<\/i> Editorial Board. He has not taken part in the review or selection process of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Dr. Michael Weber kindly provided statistical advice for this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Informed Consent was waived by the Institutional Review Board.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was obtained. Ethics commission (EC), Nr: 2249\/2016 Radiologic Diagnosis of Cholestatic Liver Disease; A Retrospective Data Analysis.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Some study subjects or cohorts have been previously reported in Poetter-Lang S, Messner A, Bastati N et al (2023) Diagnosis of functional strictures in patients with primary sclerosing cholangitis using hepatobiliary contrast-enhanced MRI: a proof-of-concept study. <i>Eur Radiol 33<\/i>(12):9022-9037. . In the above-mentioned previous study, this cohort was used to prove the efficacy of potential functional stricture (PFS) to diagnose dominant or functional stricture in patients with PSC using ERCP as the gold standard. In this current study, this cohort is used to compare between the Anali scores and PFS to predict the short-, and mid to long term outcome of PSC patients.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study subjects or cohorts overlap"}},{"order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}